Published Date:2021-02-02
Original Link:https://www.onenessbio.com/en/news_detail25_4.htm
| No | 1 | Date of announcement | 2021/02/02 | Time of announcement | 21:33:43 |
|---|---|---|---|---|---|
| Subject | Oneness Biotech Co.,LTD receives a U.S. patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on the developing new drug: ON101 Cream. | ||||
| To which item it meets |
paragraph 53 | Date of events | 2021/02/02 | ||
| Statement | |||||
|
1.Date of occurrence of the event:2021/02/02
2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:The Company has been informed by the patent agency that the developing new drug:ON101 Cream has been granted a U.S. patent titled ”TOPICAL FORMULATION FOR PROMOTING WOUND HEALING”underpatent number US 10,758,584 B2. 6.Countermeasures:None 7.Any other matters that need to be specified: (1)This patent, which will expire on July 24, 2038, is a crucial patent for the new drug ON101 Cream developed by Oneness Biotech Co., LTD as this will prevent its generic formulation considering the U.S. as the largest market for advance wound care. (2)The patent application for ”TOPICAL FORMULATION FOR PROMOTING WOUND HEALING”has also been filed in major countries or regions of the global markets, and currently under review. (3)ON101 Cream, a new drug for the treatment of the diabetic foot ulcers, is currently undergoing New Drug Application in Taiwan, and will be launched into the market firstly in Asia after the approval. (4)The second phase 3 clinical trial greenlighted by USFDA will be initiated in the second quarter of this year and plan to enroll 208 patients in the U.S.. |
|||||